

**WEST**☐ **Generate Collection** **Print**

L13: Entry 10 of 11

File: DWPI

Sep 17, 1992

DERWENT-ACC-NO: 1992-360693

DERWENT-WEEK: 199244

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Glycyrrhizin suppository with improved rectal absorption - contains nonionic surfactant and/or middle chain fatty acid salt

PATENT-ASSIGNEE:

ASSIGNEE

CODE

SANTEN PHARM CO LTD

SANT

PRIORITY-DATA: 1991JP-0042894 (February 14, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 04261117 A	September 17, 1992		003	A61K009/02

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP04261117A	February 14, 1991	1991JP-0042894	

INT-CL (IPC): A61K 9/02; A61K 31/705

ABSTRACTED-PUB-NO: JP04261117A

BASIC-ABSTRACT:

Suppository of glycyrrhizin or its salts contains a nonionic surfactant and/or middle-chain fatty acid salt as an absorption enhancer.

USE/ADVANTAGE - The rectal absorption of glycyrrhizin is improved. The dose of glycyrrhizin is 10-500 mg.

In an example, Witepsol (1440mg) was melted at 45 deg. C and added with polyoxyethylene lauryl ether (80mg) under stirring. Monoammonium glycyrrhizinate (80mg) passed through a 200 mesh sieve was dispersed in the mixt. uniformly and charged into a container for a suppository. After rectal admin. to a beagle dog, AUC 0-24 hrs. was 202.9 (microg.h/ml) in example, while 16.2 (microg.h/ml) in reference (without POE lauryl ether).

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: GLYCYRRHIZIN SUPPOSITORY IMPROVE RECTUM ABSORB CONTAIN NONIONIC SURFACTANT MIDDLE CHAIN FATTY ACID SALT

DERWENT-CLASS: B03

CPI-CODES: B07-A02; B12-M08;

CHEMICAL-CODES:

Chemical Indexing M2 \*01\*  
Fragmentation Code